Reuters logo
BRIEF-Atyr Pharma announces promising top-line results from Resolaris
2017年4月24日 / 中午12点15分 / 5 个月前

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

April 24 (Reuters) - Atyr Pharma Inc

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

* Resolaris generally well-tolerated at doses up to 3.0 mg/kg once weekly in early onset facioscapulohumeral muscular dystrophy

* Atyr believes observed safety results of Resolaris to date are supportive of further advancement of resolaris Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below